{"contentid": 488193, "importid": NaN, "name": "GSK rides to rescue as UK eyes neighbors nervously", "introduction": "British drugmaker GlaxoSmithKline has agreed to provide fill and finish services for Novavax\u00e2\u0080\u0099 coronavirus vaccine, supplying 60 million doses for domestic use.", "content": "<p><span style=\"font-weight: 400;\">British drugmaker GlaxoSmithKline (LSE: GSK) has agreed to provide fill and finish services for Novavax&rsquo; (Nasdaq: NVAX) coronavirus vaccine, supplying 60 million doses for domestic use.</span></p>\n<p><span style=\"font-weight: 400;\">In the fight against COVID-19, fellow UK-based pharma major AstraZeneca (LSE: AZN) has made most of the headlines thus far, with a successful vaccine rollout accompanied by </span><a href=\"https://www.thepharmaletter.com/article/more-positive-data-clarify-picture-on-astrazeneca-jab\"><span style=\"font-weight: 400;\">a degree of political turmoil</span></a><span style=\"font-weight: 400;\">.</span></p>\n<h2><strong>Vaccine nationalism</strong></h2>\n<p><span style=\"font-weight: 400;\">While UK Prime Minister Boris Johnson trumpeted the &ldquo;strength of UK manufacturing&rdquo; evident in the deal, the political furore surrounding AstraZeneca&rsquo;s vaccine seems to have motivated the move towards bringing manufacturing within the UK.</span></p>\n<p><span style=\"font-weight: 400;\">European officials, under pressure to secure reliable supplies for EU-27 nations, have previously threatened to block exports of vaccines from the continent.</span></p>\n<p><span style=\"font-weight: 400;\">After talks with Novavax and the UK government Vaccines Taskforce, GSK agreed to provide fill and finish services at its Barnard Castle-based facility, with a rapid technology transfer between the two companies beginning immediately.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">GSK&rsquo;s own vaccine program has been beset with delays, although the firm has more recently </span><a href=\"https://www.thepharmaletter.com/article/end-to-gsk-losing-streak-brings-hope-for-covid-19-patients\"><span style=\"font-weight: 400;\">made significant progress</span></a><span style=\"font-weight: 400;\"> with VIR-7831, a Vir Biotechnology-partnered (Nasdaq: VIR) antibody treatment.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The firm said its agreement with Novavax would not impact on timelines for its coronavirus development projects.</span></p>\n<h2><strong>Novavax agreement</strong></h2>\n<p><span style=\"font-weight: 400;\">The UK government has secured doses of NVX-CoV2373 from the US biotech under an advance purchase agreement.</span></p>\n<p><span style=\"font-weight: 400;\">The protein antigen component of NVX-CoV2373 is also produced in England by Novavax&rsquo; manufacturing partner, FUJIFILM Diosynth Biotechnologies.</span></p>\n<p><span style=\"font-weight: 400;\">NVX-CoV2373 has been shown to be safe and effective in Phase III clinical trials, and a regulatory decision is expected imminently. If approved, GSK could begin delivering finished product as early as June.</span></p>\n<p><span style=\"font-weight: 400;\">GSK vaccines president Roger Connor said: &ldquo;GSK is delighted to support Novavax and the UK Vaccines Taskforce with this manufacturing arrangement for the UK.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;We have ensured that we can deliver these volumes without impacting supply of our other vital medicines and vaccines, and without disruption to the other COVID-19 collaborations GSK is engaged in globally.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">Novavax has also agreed to supply over a billion doses of its vaccine to low- and middle-income countries through the COVAX initiative.</span></p>", "date": "2021-03-30 10:35:00", "meta_title": NaN, "meta_keywords": "vaccine, Novavax, vaccines, agreed, doses, manufacturing, fill, services, finish, Nasdaq, provide, coronavirus, agreement, NVX-CoV, supplying, domestic", "meta_description": "British drugmaker GlaxoSmithKline has agreed to provide fill and finish services for Novavax\u00e2\u0080\u0099s (Nasdaq: NVAX) coronavirus vaccine, supplying 60 million doses fo", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-30 10:18:59", "updated": "2021-03-30 10:37:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/gsk-rides-to-rescue-as-uk-eyes-neighbors-nervously", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "glaxo_gsk_glaxosmithkline_big.jpg", "image2id": "glaxo_gsk_glaxosmithkline_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Focus On, Government Affairs, Production, Research", "geography_tag": "Europe, UK", "company_tag": "AstraZeneca, GlaxoSmithKline, Novavax", "drug_tag": "NVX-CoV2373", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-30 10:35:00"}